Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Takahashi N, Miura I, Kobayashi Y, Kume M, Yoshioka T, Otane W, Ohtsubo K, Takahashi K, Kitabayashi A, Kawabata Y, Hirokawa M, Nishijima H, Ichinohasama R, Decoteau J, Miura AB, Sawada K. Takahashi N, et al. Among authors: ohtsubo k. Int J Hematol. 2005 Apr;81(3):235-41. doi: 10.1532/IJH97.04095. Int J Hematol. 2005. PMID: 15814334 Clinical Trial.
Deletion 6p23 and add(11)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia.
Takeshita A, Naito K, Shinjo K, Sahara N, Matsui H, Ohnishi K, Beppu H, Ohtsubo K, Horii T, Maekawa M, Inaba T, Ohno R. Takeshita A, et al. Among authors: ohtsubo k. Cancer Genet Cytogenet. 2004 Jul 1;152(1):56-60. doi: 10.1016/j.cancergencyto.2003.10.002. Cancer Genet Cytogenet. 2004. PMID: 15193442
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Andre T, et al. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. N Engl J Med. 2024. PMID: 39602630 Clinical Trial.
Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors.
Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, Yoshino T. Hashimoto T, et al. Among authors: ohtsubo k. BJC Rep. 2024 Jul 25;2(1):54. doi: 10.1038/s44276-024-00073-7. BJC Rep. 2024. PMID: 39516322 Free PMC article.
Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.
Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo K, Sekiya T, Watanabe A, Tajima A, Shimaguchi C, Mizuguchi K, Ikeda H, Kinoshita M, Nakada M, Takeuchi S. Nishiyama A, et al. Among authors: ohtsubo k. Cancer Sci. 2025 Jan;116(1):271-276. doi: 10.1111/cas.16370. Epub 2024 Oct 25. Cancer Sci. 2025. PMID: 39453824 Free PMC article.
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers.
Kotani H, Yamano T, Boucher JC, Sato S, Sakaguchi H, Fukuda K, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Nishiuchi T, Oshima H, Oshima M, Davila ML, Yano S. Kotani H, et al. Among authors: ohtsubo k. Exp Hematol Oncol. 2024 Sep 27;13(1):94. doi: 10.1186/s40164-024-00563-x. Exp Hematol Oncol. 2024. PMID: 39334463 Free PMC article.
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T. Nakamura Y, et al. Among authors: ohtsubo k. Nat Med. 2024 Sep 16. doi: 10.1038/s41591-024-03244-8. Online ahead of print. Nat Med. 2024. PMID: 39284955
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.
Sudo K, Nakamura Y, Ueno M, Furukawa M, Mizuno N, Kawamoto Y, Okano N, Umemoto K, Asagi A, Ozaka M, Ohtsubo K, Shimizu S, Matsuhashi N, Itoh S, Matsumoto T, Satoh T, Okuyama H, Goto M, Hasegawa H, Yamamoto Y, Odegaard JI, Bando H, Yoshino T, Ikeda M, Morizane C. Sudo K, et al. Among authors: ohtsubo k. Br J Cancer. 2024 Oct;131(7):1237-1245. doi: 10.1038/s41416-024-02834-0. Epub 2024 Aug 28. Br J Cancer. 2024. PMID: 39198618
294 results